These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 28659046

  • 1. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men.
    Schwarting A, Relle M, Meineck M, Föhr B, Triantafyllias K, Weinmann A, Roth W, Weinmann-Menke J.
    Lupus; 2018 Feb; 27(2):243-256. PubMed ID: 28659046
    [Abstract] [Full Text] [Related]

  • 2. A benzenediamine derivate FC-99 attenuates lupus nephritis in MRL/lpr mice via inhibiting myeloid dendritic cell-secreted BAFF.
    Ji J, Xu J, Li F, Li X, Gong W, Song Y, Dou H, Hou Y.
    Acta Biochim Biophys Sin (Shanghai); 2016 May; 48(5):411-9. PubMed ID: 27121231
    [Abstract] [Full Text] [Related]

  • 3. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
    Zhou L, Sun L, Wu H, Zhang L, Chen M, Liu J, Zhong R.
    Eur J Pharmacol; 2013 Sep 05; 715(1-3):230-7. PubMed ID: 23712004
    [Abstract] [Full Text] [Related]

  • 4. Granulocytic myeloid-derived suppressor cells contribute to IFN-I signaling activation of B cells and disease progression through the lncRNA NEAT1-BAFF axis in systemic lupus erythematosus.
    Dong G, Yang Y, Li X, Yao X, Zhu Y, Zhang H, Wang H, Ma Q, Zhang J, Shi H, Ning Z, Yan F, Zhai W, Dai J, Li Z, Li C, Ming J, Xue Q, Meng X, Si C, Xiong H.
    Biochim Biophys Acta Mol Basis Dis; 2020 Jan 01; 1866(1):165554. PubMed ID: 31513833
    [Abstract] [Full Text] [Related]

  • 5. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, Suzuki J, Nozawa K, Amano H, Tokano Y, Kobata T, Takasaki Y.
    Rheumatology (Oxford); 2007 Jul 01; 46(7):1083-6. PubMed ID: 17500077
    [Abstract] [Full Text] [Related]

  • 6. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
    Vincent FB, Morand EF, Mackay F.
    Immunol Cell Biol; 2012 Mar 01; 90(3):293-303. PubMed ID: 22231653
    [Abstract] [Full Text] [Related]

  • 7. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.
    Faust J, Menke J, Kriegsmann J, Kelley VR, Mayet WJ, Galle PR, Schwarting A.
    Arthritis Rheum; 2002 Nov 01; 46(11):3083-95. PubMed ID: 12428253
    [Abstract] [Full Text] [Related]

  • 8. TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.
    Arkatkar T, Jacobs HM, Du SW, Li QZ, Hudkins KL, Alpers CE, Rawlings DJ, Jackson SW.
    Kidney Int; 2018 Oct 01; 94(4):728-740. PubMed ID: 29907458
    [Abstract] [Full Text] [Related]

  • 9. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
    Shin W, Lee HT, Lim H, Lee SH, Son JY, Lee JU, Yoo KY, Ryu SE, Rhie J, Lee JY, Heo YS.
    Nat Commun; 2018 Mar 23; 9(1):1200. PubMed ID: 29572471
    [Abstract] [Full Text] [Related]

  • 10. A novel BAFF antagonist, BAFF-Trap, effectively alleviates the disease progression of systemic lupus erythematosus in MRL/lpr mice.
    Yu C, Chen S, Zhou B, Zhang H, Su X, Luo Y, Yang L.
    Mol Immunol; 2021 Jan 23; 129():1-11. PubMed ID: 33254074
    [Abstract] [Full Text] [Related]

  • 11. Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis.
    Phatak S, Chaurasia S, Mishra SK, Gupta R, Agrawal V, Aggarwal A, Misra R.
    Clin Exp Immunol; 2017 Mar 23; 187(3):376-382. PubMed ID: 27804111
    [Abstract] [Full Text] [Related]

  • 12. Belimumab therapy in systemic lupus erythematosus.
    Zouali M, Uy EA.
    BioDrugs; 2013 Jun 23; 27(3):225-35. PubMed ID: 23568179
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N, D'Cruz DP.
    Expert Rev Clin Immunol; 2015 Feb 23; 11(2):195-204. PubMed ID: 25543845
    [Abstract] [Full Text] [Related]

  • 15. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice.
    Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR.
    J Immunol; 1998 Jul 01; 161(1):494-503. PubMed ID: 9647261
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis.
    Friebus-Kardash J, Trendelenburg M, Eisenberger U, Ribi C, Chizzolini C, Huynh-Do U, Lang KS, Wilde B, Kribben A, Witzke O, Dolff S, Hardt C.
    BMC Nephrol; 2019 Nov 21; 20(1):430. PubMed ID: 31752784
    [Abstract] [Full Text] [Related]

  • 18. IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice.
    Wada Y, Gonzalez-Sanchez HM, Weinmann-Menke J, Iwata Y, Ajay AK, Meineck M, Kelley VR.
    J Am Soc Nephrol; 2019 Feb 21; 30(2):244-259. PubMed ID: 30622154
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.